Literature DB >> 25381842

The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease.

M Makris1,2, A B Federici3, P M Mannucci4, P H B Bolton-Maggs5, T T Yee6, T Abshire7, E Berntorp8.   

Abstract

Recurrent gastrointestinal bleeding is one of the most challenging complications encountered in the management of patients with von Willebrand disease (VWD). The commonest cause is angiodysplasia, but often no cause is identified due to the difficulty in making the diagnosis. The optimal treatment to prevent recurrences remains unknown. We performed a retrospective study of VWD patients with occult or angiodysplastic bleeding within the setting of the von Willebrand Disease Prophylaxis Network (VWD PN) to describe diagnostic and treatment strategies. Centres participating in the VWD PN recruited subjects under their care with a history of congenital VWD and gastrointestinal (GI) bleeding due to angiodysplasia, or cases in which the cause was not identified despite investigation. Patients with acquired von Willebrand syndrome or those for whom the GI bleeding was due to another cause were excluded. Forty-eight patients from 18 centres in 10 countries were recruited. Seven individuals had a family history of GI bleeding and all VWD types except 2N were represented. Angiodysplasia was confirmed in 38%, with video capsule endoscopy and GI tract endoscopies being the most common methods of making the diagnosis. Recurrent GI bleeding in VWD is associated with significant morbidity and required hospital admission on up to 30 occasions. Patients were treated with multiple pharmacological agents with prophylactic von Willebrand factor concentrate being the most efficient in preventing recurrence of the GI bleeding. The diagnosis and treatment of recurrent GI bleeding in congenital VWD remains challenging and is associated with significant morbidity. Prophylactic treatment with von Willebrand factor concentrate was the most effective method of preventing recurrent bleeding but its efficacy remains to be confirmed in a prospective study.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  angiodysplasia; gastrointestinal bleeding; thalidomide; von Willebrand disease

Mesh:

Year:  2014        PMID: 25381842     DOI: 10.1111/hae.12571

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  15 in total

1.  Our findings differ.

Authors:  Bartosz Hudzik; Krzysztof Wilczek; Mariusz Gasior
Journal:  CMAJ       Date:  2015-10-20       Impact factor: 8.262

Review 2.  Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Authors:  Piercarla Schinco; Giancarlo Castaman; Antonio Coppola; Dorina Cultrera; Cosimo Ettorre; Anna C Giuffrida; Emanuela Marchesini; Renato Marino; Marta Milan; Claudio Molinari; Simona M Siboni; Ezio Zanon; Augusto B Federici
Journal:  Blood Transfus       Date:  2017-05-26       Impact factor: 3.443

Review 3.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

4.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

5.  Recurrent Gastrointestinal Bleeding from Dieulafoy's Lesions in a Patient with Type 1 von Willebrand Disease: A Rare Association.

Authors:  Mariana Ferreira Cardoso; Luís Carvalho Lourenço; Margarida Antunes; Joana Carvalho E Branco; Liliana Santos; Alexandra Martins; Jorge A Reis
Journal:  GE Port J Gastroenterol       Date:  2018-08-24

Review 6.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

7.  Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report.

Authors:  Racquel Brown
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

Review 8.  Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Authors:  Jessica M Heijdra; Marjon H Cnossen; Frank W G Leebeek
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

9.  Thalidomide for the Treatment of Gastrointestinal Bleeding Due to Angiodysplasia in a Patient with Glanzmann's Thrombasthenia.

Authors:  Bruno K L Duarte; Sílvia M de Souza; Carolina Costa-Lima; Samuel S Medina; Margareth C Ozelo
Journal:  Hematol Rep       Date:  2017-06-15

10.  Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients With Ventricular Assist Devices.

Authors:  Ulrich Geisen; Kerstin Brehm; Georg Trummer; Michael Berchtold-Herz; Claudia Heilmann; Friedhelm Beyersdorf; Johannes Schelling; Axel Schlagenhauf; Barbara Zieger
Journal:  J Am Heart Assoc       Date:  2018-01-13       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.